12:00 AM
 | 
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Halaven eribulin mesylate regulatory update

Eisai said Health Canada approved its Halaven eribulin mesylate to treat metastatic breast cancer in patients who have previously...

Read the full 73 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >